Johnson & Johnson beats estimates, raises guidance

|About: Johnson & Johnson (JNJ)|By:, SA News Editor

Shares of Johnson & Johnson (JNJ) are up 1.8% premarket following the company's top and bottom line Q3 beat.

Domestic sales rise 1.7% for the quarter, while international sales jump 4.2%.

Diluted EPS +8.8% Y/Y.

Global consumer sales come in at $3.6B, up 2% Y/Y ex-currency impact.

Global pharmaceutical sales rise 10.9% (ex-currency impact) to $7B.

Worldwide medical devices sales of $6.9B rise slightly, but fall when adjusted for a negative currency impact of 2.3%.

FY13 EPS guidance raised to $5.44-5.49 from $5.40-5.47. Consensus is $5.46. (PR)